|
JP2008507288A
(ja)
|
2004-07-23 |
2008-03-13 |
アクセルロン ファーマ インコーポレーテッド |
ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
|
|
US8128933B2
(en)
|
2005-11-23 |
2012-03-06 |
Acceleron Pharma, Inc. |
Method of promoting bone growth by an anti-activin B antibody
|
|
BRPI0618947B1
(pt)
|
2005-11-23 |
2022-07-19 |
Acceleron Pharma Inc |
Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea
|
|
US8895016B2
(en)
|
2006-12-18 |
2014-11-25 |
Acceleron Pharma, Inc. |
Antagonists of activin-actriia and uses for increasing red blood cell levels
|
|
TWI584815B
(zh)
|
2007-02-01 |
2017-06-01 |
艾瑟勒朗法瑪公司 |
活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途
|
|
TW201627320A
(zh)
|
2007-02-02 |
2016-08-01 |
艾瑟勒朗法瑪公司 |
衍生自ＡｃｔＲＩＩＢ的變體與其用途
|
|
MX2009008510A
(es)
|
2007-02-09 |
2010-01-15 |
Acceleron Pharma Inc |
Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer.
|
|
CA2699936A1
(en)
|
2007-09-18 |
2009-03-26 |
Acceleron Pharma Inc. |
Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
|
|
US8216997B2
(en)
|
2008-08-14 |
2012-07-10 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
|
|
DK3750552T5
(da)
|
2008-08-14 |
2024-08-26 |
Acceleron Pharma Inc |
Gdf-fælder
|
|
WO2011063127A1
(en)
|
2009-11-18 |
2011-05-26 |
University Of Medicine And Dentistry Of New Jersey |
Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
|
|
AU2010204985A1
(en)
|
2009-01-13 |
2011-08-04 |
Acceleron Pharma Inc. |
Methods for increasing adiponectin
|
|
MX355042B
(es)
|
2009-06-08 |
2018-04-02 |
Acceleon Pharma Inc |
Metodos para aumentar adipositos termogenicos.
|
|
CN107267520A
(zh)
|
2009-06-12 |
2017-10-20 |
阿塞勒隆制药公司 |
截短的actriib‑fc融合蛋白
|
|
CA2771575A1
(en)
|
2009-08-29 |
2011-03-03 |
Abbott Laboratories |
Therapeutic dll4 binding proteins
|
|
ES2658292T3
(es)
|
2009-11-17 |
2018-03-09 |
Acceleron Pharma, Inc. |
Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
|
|
US9849192B2
(en)
|
2009-11-18 |
2017-12-26 |
Rutgers, The State University Of New Jersey |
Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
|
|
CA2781682A1
(en)
*
|
2009-12-04 |
2011-06-09 |
Genentech, Inc. |
Multispecific antibodies, antibody analogs, compositions, and methods
|
|
US20120288507A1
(en)
|
2009-12-18 |
2012-11-15 |
Amgen Inc. |
Wise binding agents and epitopes
|
|
WO2011109298A2
(en)
|
2010-03-02 |
2011-09-09 |
Abbott Laboratories |
Therapeutic dll4 binding proteins
|
|
CA2817008A1
(en)
|
2010-11-08 |
2012-05-18 |
Acceleron Pharma Inc. |
Actriia binding agents and uses thereof
|
|
AU2012327223A1
(en)
|
2011-11-30 |
2013-06-20 |
Wellstat Diagnostics, Llc. |
Assays, antibodies, immunogens and compositions related to 5-FU
|
|
TW201333040A
(zh)
*
|
2012-01-06 |
2013-08-16 |
Bioalliance Cv |
抗－輸鐵蛋白受器之抗體及其使用方法
|
|
FR2987293B1
(fr)
*
|
2012-02-27 |
2014-03-07 |
Michelin & Cie |
Procede et appareil pour realiser des objets tridimensionnels a proprietes ameliorees
|
|
EP2904015A4
(en)
*
|
2012-10-02 |
2016-10-05 |
Univ Rutgers |
TARGETED RELEASE OF ANTIBODIES TO ACTIVATED MATRIPTASE-CONJUGATED TOXINS
|
|
RU2678117C2
(ru)
|
2012-11-02 |
2019-01-23 |
Селджин Корпорейшн |
Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
|
|
KR102149206B1
(ko)
|
2012-11-08 |
2020-08-31 |
세센 바이오, 아이엔씨. |
인터루킨-6의 길항제 및 이의 용도
|
|
US20140171356A1
(en)
*
|
2012-12-12 |
2014-06-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chemically immobilized wnt protein and methods of use
|
|
AU2014315081A1
(en)
|
2013-09-05 |
2016-03-24 |
Duke University |
Nav1.7 antibodies and methods of using the same
|
|
US10035847B2
(en)
|
2013-10-02 |
2018-07-31 |
The Rockefeller University |
Amyloid protofibril antibodies and methods of use thereof
|
|
CN114699529A
(zh)
|
2014-06-13 |
2022-07-05 |
阿塞勒隆制药公司 |
用于治疗溃疡的方法和组合物
|
|
MA41052A
(fr)
|
2014-10-09 |
2017-08-15 |
Celgene Corp |
Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
|
|
SI3215530T1
(sl)
|
2014-11-07 |
2020-02-28 |
Sesen Bio, Inc. |
Izboljšana protitelesa IL-6
|
|
EP3227675B1
(en)
|
2014-12-03 |
2023-03-15 |
Celgene Corporation |
Activin-actrii antagonists and uses for treating myelodysplastic syndrome
|
|
BR112018017031A2
(pt)
|
2016-02-23 |
2019-01-22 |
Sesen Bio Inc |
formulações de antagonista de il-6 e usos das mesmas
|
|
IL261757B2
(en)
|
2016-03-18 |
2023-09-01 |
Univ Rutgers |
Treatment of stem cells with chemotherapeutic agents conjugated to anti-matriptase antibodies using connecting parts that can be broken down in the living body
|
|
WO2017189963A1
(en)
*
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
CA3049967C
(en)
*
|
2017-01-06 |
2024-10-01 |
The Regents Of The University Of California |
ANTI-IgE ANTIBODIES: THERAPIES AND ASSOCIATED METHODS AND COMPOSITIONS
|
|
JP7795860B2
(ja)
|
2017-09-07 |
2026-01-08 |
オーガスタ ユニバーシティ リサーチ インスティテュート，インコーポレーテッド |
プログラム細胞死タンパク質１に対する抗体
|
|
JP7572668B2
(ja)
*
|
2019-07-12 |
2024-10-24 |
国立大学法人京都大学 |
歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体
|
|
CN112180099B
(zh)
*
|
2020-09-15 |
2022-07-29 |
江南大学附属医院 |
子宫内膜异位症血清标志物的应用
|
|
WO2023147470A2
(en)
|
2022-01-28 |
2023-08-03 |
Georgiamune Inc. |
Antibodies to programmed cell death protein 1 that are pd-1 agonists
|
|
CN115322258B
(zh)
*
|
2022-05-31 |
2024-08-13 |
武汉真福医药股份有限公司 |
一种单克隆抗体qkma-1g41及其应用
|
|
CN115304677B
(zh)
*
|
2022-06-19 |
2024-08-16 |
湖北真福医药有限公司 |
一种抗枯草芽孢杆菌纤溶酶的单克隆抗体qkma-9a10及应用
|
|
CN116712533B
(zh)
*
|
2023-07-03 |
2024-02-02 |
广东暨安特博生物科技有限公司 |
一种sostdc1蛋白在制备治疗皮肤病产品中的应用
|
|
US20260184784A1
(en)
*
|
2024-09-26 |
2026-07-02 |
The Trustees Of Indiana University |
Antibodies for multiple myeloma treatment
|